Expression of the thymus leukemia antigen in mouse intestinal epithelium by Hershberg, Robert et al.
Proc. Nati. Acad. Sci. USA
Vol. 87, pp. 9727-9731, December 1990
Immunology
Expression of the thymus leukemia antigen in mouse
intestinal epithelium
(major histocompatibility complex/class lb molecules/mucosal immunology)
ROBERT HERSHBERG*, PIROOz EGHTESADY*, BEATE SYDORA*, KURT BRORSONt, HILDE CHEROUTRE*,
ROBERT MODLINt, AND MITCHELL KRONENBERG*
*Department of Microbiology and Immunology and the Jonsson Comprehensive Cancer Center, University of California at Los Angeles School of Medicine,
Los Angeles, CA 90024; tDivision of Biology, California Institute of Technology, Pasadena, CA 90025; and tDepartment of Medicine, University of Southern
California School of Medicine, Los Angeles, CA 90033
Communicated by Ray D. Owen, August 29, 1990 (received for review July 23, 1990)
ABSTRACT The Qa and TIa regions of the mouse major
histocompatibility complex contain a series of genes encoding
proteins with structural similarity to the class I transplantation
antigens of the same complex. In contrast to the genes encoding
the transplantation antigens, the Qa and TIa genes show very
little polymorphism. Function(s) of the proteins encoded by the
Qa and TIa loci remain an enigma. Recently, the protein
products of the Qa and TIa loci, often referred to as class lb
major histocompatibility complex molecules, have been pro-
posed to present antigen to y6T cells. In mice, y8 T cells have
been found concentrated in several epithelial barriers and in
the skin; yet, expression of serologically detectable Tla antigens
is believed restricted to thymocytes, activated T lymphocytes,
and some T-cell leukemias. Here we report that luminal
epithelial cells of the mouse small intestine express the thymus
leukemia antigen (TLA). We also find that, unlike T cells in
Peyer's patches, a significant fraction of intestinal epithelial
lymphocytes also express TLA. RNA prepared from intestinal
cells contains transcripts of the T18d gene, which encodes TLA.
These data extend the known expression profile of TLA mol-
ecules to mature lymphocytes and to nonhematopoietic cells.
These data also demonstrate the specific expression of TLA on
antigen-presenting cells in a site enriched for T cells that
express y6 T-cell antigen receptor.
The major histocompatibility complex (MHC) of the mouse
spans over 600 kilobases (kb) on chromosome 17 and con-
tains the genes encoding both class I and class II MHC
molecules (for review, see ref. 1). The genes of the class I
family can be subdivided into the K, D, Qa, Tia, and Hmt
regions based on immunogenetic mapping of the MHC locus.
Function ofthe classical transplantation antigens ofthe Kand
D regions of the MHC in presentation of peptide antigens to
cytotoxic T lymphocytes is well established. However, func-
tion(s) of the more telomeric genes of the Qa, Tia, and Hmt
regions of the MHC, sometimes collectively referred to as
class lb genes, remain unknown (for review, see ref. 2).
Whereas the surface expression of the K and D transplan-
tation antigens is seen on most somatic tissues, the expres-
sion of class lb molecules is believed to be more restricted.
For example, expression of the thymus leukemia antigen
(TLA), a serological determinant encoded by the TIa region,
has been observed primarily in thymocytes, activated T
lymphocytes, and in some T-cell leukemias (3, 4). Moreover,
compared with classical transplantation genes of the H-2
region, which display a high degree of polymorphism be-
tween individuals, genes of the Tla region are less polymor-
phic (5). The TLA protein is closely related structurally to the
K and D transplantation antigens and associates with /32-
microglobulin. Yet, the expression profile described for TLA
and its lack of polymorphism are not expected for a molecule
with a role in antigen presentation.
Although cell-mediated immune responses to the TLA
molecule have not been reported, recently several groups
have described y8 T-cell lines and T-cell hybridomas reactive
to allogeneic Tla-encoded molecules or that are specific for
antigen in the context of a Tla gene product (6-8). These
findings have led to the hypothesis that one function of the
products of the Tla region may be to present antigens,
possibly conserved antigens or "stress" proteins, to T cells
that express y8 T-cell antigen receptor (TCR) (9, 10). If this
hypothesis were correct, Tla region genes should be ex-
pressed on antigen-presenting cells in a site (or sites) that
contain y3 T cells. One such site in the mouse is the intestinal
epithelium, where a significant fraction of T cells express y8
TCR. Indeed, Itohara et al. (11) have recently shown the
presence of 'y T cells in several mucosal epithelial barriers.
Here we report that TLA, a serological determinant encoded
by the Tla locus of the MHC, is expressed on epithelial cells
of the mouse small intestine but not in other anatomical sites
containing y6T cells. We also demonstrate that the T18d gene
(formerly referred to as the T13' gene), which encodes TLA
is expressed in the intestinal epithelium. Moreover, we show
that, in contrast to other T lymphocytes in the intestine, a
significant fraction of intestinal lymphocytes (IEL) also ex-
press TLA.
MATERIALS AND METHODS
Mice. B10.BR, BALB/c, and C57BL/6 mice were bred in
our animal colony from breeding pairs originally obtained
from The Jackson Laboratory. Eight- to 12-week-old mice of
both sexes were used in these studies. BALB/c scid/scid
mice were a gift of 0. Witte (University of California at Los
Angeles).
Preparation of Cells. Thymuses were dissected into RPMI
1640 medium, and single-cell suspensions were prepared by
dissociating the tissue with glass microscope slides. The cells
were passed through nylon mesh and maintained on ice in
RPMI 1640/10% fetal bovine serum until use. IEL were
prepared essentially as described (12). Briefly, the entire
small intestine was removed and flushed with Ca2+/Mg2+-
free Hanks' balanced salt solution. Peyer's patches were
dissected away, and the intestine was cut longitudinally into
-10-mm pieces. These pieces were incubated twice for 15
min at 370C in phosphate-buffered saline/1 mM EDTA/1 mM
dithiothreitol. Cells were collected from the supernatants
Abbreviations: FITC, fluorescein isothiocyanate; IEL, intestinal
epithelial lymphocyte(s); MHC, major histocompatibility complex;
mAb, monoclonal antibody; PCR, polymerase chain reaction; TCR,
T-cell antigen receptor; TLA, thymus leukemia antigen.
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after each wash, filtered through nylon mesh, and washed
once in RPMI 1640 medium. The pooled cells were then
passed over a 40-80% discontinuous Percoll gradient. Cells
at the interface were collected, washed several times, and
kept on ice until use. The approximate yield was 1-2 x 107
cells per mouse. Single-cell supensions of Peyer's patch
lymphocytes were prepared from pooled, dissected Peyer's
patches that were dissociated with glass microscope slides.
Cells were maintained on ice in RPMI 1640 medium/10%
fetal bovine serum until use.
Antibodies. Two mouse monoclonal antibodies (mAbs),
TL.m4 and TL.m9, specific for the TLA expressed on ASL.1
thymic leukemia cells have been described (13) and were
provided by E. Boyse and K. Kimura (Memorial Sloan-
Kettering, New York). The TLA-specific rat mAb, HD168
(14) was from E. Stockert and L. Old (Memorial Sloan-
Kettering). Mouse mAb 695 H1-7-3, which reacts with the
Qa-2 determinant (15), was from D. Sachs (National Insti-
tutes of Health). Hamster mAb 145-2C11 is directed against
the E subunit of CD3 complex (16) and was from J. Bluestone
(University of Chicago). Hamster mAb H57-597 recognizes
mouse a/t3 TCR (17) and was from R. Kubo (University of
Colorado, Denver). mAb G8.8 reacts with intestinal epithelial
cells and was from A. Farr (University of Washington,
Seattle). Where indicated, the antibodies were biotinylated or
directly coupled to fluorescein isothiocyanate (FITC) by
using standard techniques (18). FITC-coupled anti-Lyt-2 was
purchased from Becton Dickinson, and FITC-coupled anti-
Thy-1 was purchased from Caltag Laboratories (San Fran-
cisco). Anti--y8 TCR mAb GL3 was purchased from Pharmin-
gen (San Diego).
Flow Cytometry Analysis. Cells were treated with the above
mAb for 30 min at 4TC in phosphate-buffered saline, pH
7.4/2% bovine serum albumin/0.1% sodium azide and
washed several times in the same buffer. When the mAb was
not directly FITC-coupled, the cells were treated with an
appropriate second antibody or streptavidin-phycoerythrin
for 30 min at 40C. Cells were then washed two times in
staining buffer and resuspended in phosphate-buffered sa-
line/1% paraformaldehyde. The samples were run on a
FACScan flow cytometer (Becton Dickinson immunocytom-
etry systems) equipped with a 15-mW 488-nm air-cooled
argon-ion laser. The flow cytometer was equipped with
Autocomp software (Becton Dickinson) that optimizes FSC
(forward light scatter) and SSC [side (right angle) light
scatter] settings to distinguish populations of lymphocytes
from monocytes and granulocytes based on their size and
granularity, respectively, and automatically adjusts the flu-
orescence photomultiplier tube settings and compensation.
Five thousand events were acquired by using FACScan
research (Becton Dickinson) software. The green fluores-
cence (FITC) channel uses a 530 ± 30 nm band-pass filter in
front of the photomultiplier tube. The orange fluorescence
(phycoerythrin) uses a 585 ± 42 nm band-pass filter. Single-
and multi-parameter analysis using single histograms and
contour plots and corresponding statistics were used. Over-
lays of histograms were created in FACScan research soft-
ware.
Immunohistochemistry. Fresh tissues were snap-frozen in
OCT embedding medium and stored at -80°C until use.
Five-micrometer sections were cut on a microtome, fixed for
10 min in acetone, and stained in phosphate-buffered saline
by using biotinylated mAb followed by avidin-horseradish
peroxidase conjugates, as described (19). The sections were
counterstained with Mayer's hematoxylin. Adjacent sections
were stained with avidin-horseradish peroxidase conjugates
alone to ensure specificity of the staining pattern.
Polymerase Chain Reaction (PCR) Analysis. RNA was
prepared from tissues as described (20), and oligo(dT)-primed
single-stranded cDNA was synthesized from 100 ,.g of total
RNA. Before cDNA synthesis, all RNA preparations were
treated with RNase-free DNase (Stratagene) to eliminate
contaminating genomic DNA. PCR amplification was con-
ducted in a total volume of 50 using Thermus aquaticus
(Taq) I polymerase (Cetus) in a thermal cycling machine
(Ericomp, San Diego). Sequences of the T18"-specific prim-
ers are as follows: (exon 2) 5'-ATAAGCTAAGTGCGC-
CATGGGTGG-3' and (exon 3) 5'-TTATGAGCAGCATG-
GCTATGATGGCC-3'. Sequences of the primers for the
other Tla region genes are described elsewhere (P.E., K.B.,
R.H. and M.K., unpublished work). In this paper, we use the
nomenclature for Tla genes recently proposed by Klein et al.
(21). After 25 cycles, 10 ,ul of the PCR reaction was electro-
phoresed on 2% agarose gel, transferred to a nylon membrane
(Oncor, Gaithersburg, MD), and hybridized with probes
specific for the indicated Tia region genes (ref. 22, and P.E.,
K.B., R.H. and M.K., unpublished work). The membranes
were washed at high stringency (650C and 0.1 x SSC; 1x SSC
is 0.15 M sodium chloride/0.015M sodium citrate, pH 7.) and
exposed for autoradiography.
RESULTS
Specificity of TLA mAbs. Results of previous serological
studies have led to the designation of several Tla haplotypes
based on reactivity of both polyclonal antibodies and mAbs
with thymocytes from a variety of inbred mouse strains (13).
We used the TLA-specific mAbs TL.m9 and TL.m4, both
products of immunization of (B6 x A.Tlab)Fj mice with the
Tlaa-strain leukemia ASLi (13). As summarized in Table 1,
when cell suspensions were analyzed by flow cytometry,
mAb TL.m9 was specific for thymocytes from Tlaa haplotype
mice (e.g., B10.BR), mAb TL.m4 reacted with both Tlaa and
Tlad thymocytes (e.g., B10.BR and BALB/c), and neither
antibody reacted with Tlab thymocytes (e.g., C57BL/6) (data
not shown). This pattern is consistent with that obtained with
the same mAb by using other techniques, such as comple-
ment-mediated lysis (13). By using fibroblasts transfected
with individual Tla genes cloned from BALB/c DNA, it has
been shown that fibroblasts expressing T18d but not other Tla
region genes react with mAb TL.m4 (23). Rat mAb HD168
also reacted with thymocytes from both Tlaa and Tlad hap-
lotypes (23, 24) and stains transfectants expressing T18d
(R.H., K.B., H.C., and M.K., unpublished work).
Staining of Preparations of Thymocytes and EEL with TLA
mAbs. Our preparations of murine thymocytes are a rela-
tively homogenous population of small, nongranular cells
when analyzed by flow cytometry by using the parameters of
forward and right-angle light scatter. As expected, >90% of
thymocytes from 7- to 10-week-old B10.BR mice stained
brightly with the TLA-specific mAb TL.m9 (Fig. 1A). In
marked contrast, our preparations ofIEL are a heterogenous
mixture of cells containing both T lymphocytes and epithelial
cells. These cell populations can be clearly distinguished and
separated by gating on the basis of forward and right-angle
light scatter. Based upon staining with a variety of antibodies
and gating on different populations of cells, these prepara-
tions can be clearly divided into two distinct types of cells: (i)
small nongranular cells that are >85% CD3+, "70%
CD8+CD4-, 5-10% CD8-CD4+, and 5-10% CD8+CD4+
(data not shown) and are, therefore, predominantly T lym-
phocytes and (ii) large granular cells that are <5% CD3+ and
Table 1. Strain specificity of anti-TLA mAbs
mAb B1O.BR (Tlaa) C57BL/6 (Tiab) BALB/c (Tiad)
TL.m4 ++ - +
TL.m9 + + - -
HD168 + + - +
Strain specificity is based on staining of thymocytes as described.
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<5% CD8+ and that stain brightly with mAb G8.8, known to
react with intestinal epithelial cells (data not shown, and A.
Farr, personal communication); this latter population is com-
posed mostly of intestinal epithelial cells.
Staining of an IEL preparation from B10.BR mice with
mAb TL.m9 and gating on the different cell populations is
shown in Fig. 1. In contrast to cells of Peyer's patches that
did not stain appreciably for TLA (Fig. 1B), -50% of the
lymphocytes (IEL) in the preparation were TLA+ (Fig. 1C).
Surprisingly most large, granular epithelial cells were also
strongly TLA+ (Fig. 1D). As shown by Fig. 1, although
reproducibly above background, the amount of TLA ex-
pressed on IEL was -10-fold less than that seen on thymo-
cytes. Because background staining was so much higher on
epithelial cells than on lymphocytes, comparing relative
amounts between these two cell types by using this technique
is difficult. These results were confirmed by use of mAbs
TL.m4 and HD168 on similar IEL preparations from both
B10.BR and BALB/c mice (data not shown). Intestinal cells
from C57BL/6 mice did not react with either mAb TL.m4 or
mAb TL.m9. Note that the haplotype specificity of mAbs
TL.m4 and TL.m9 in IEL preparations precisely followed
what we and others have previously described for thymo-
cytes (Table 1).
Greater than 90% of the lymphocytes in the IEL prepara-
tions stained brightly with several anti-Qa2 mAbs, whereas
the epithelial cells were completely negative (data not
shown).
Phenotypic Analysis of TLA' IEL. Two-color flow-
cytometric analysis with antibodies to a variety of T-lym-
phocyte surface markers was done to further analyze the
population of IEL that express TLA. In general, we find that
IEL contain roughly equal numbers of a,8 and Hy T cells. Fig.
2 shows that TLA was expressed on most IEL expressing a/3
TCR but was found only on a small fraction of cells express-
ing y8 TCR. Our IEL preparations contain 40-65% Thy-i+
cells. Antibodies to Thy-1 can stimulate T-cell proliferation
(25), and Thy-1 is a reported marker of IEL activation (26).
Most Thy-1+ cells in our preparations were TLA-, although
there was a small population of Thy-1+ TLA+ cells (Fig. 2).
Immunohistochemistry on Intestinal Sections. To further
clarify the location of the cells in the intestinal tract that
express TLA, we examined its expression in situ by staining
fixed tissue sections with the TLA-specific mAb. Fig. 3B
shows that all luminal epithelial cells were positive for
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FIG. 1. Analysis of TLA expression in thymocytes and in IEL
preparations. Cells from B1O.BR mice were prepared as described
and were stained with biotinylated mAb TL.m9 and then by strepta-
vidin-phycoerythrin. For IEL preparations, cells were "gated" as
lymphocytes or epithelial cells as described. Staining with mAb
TL.m9 is shown by the solid line, and staining by streptavidin-
phycoerythrin alone is shown by the dotted line. (A) Thymocytes. (B)
Peyer's patch lymphocytes. (C) IEL. (D) Intestinal epithelial cells.
Logarithms are to the base ten.
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FIG. 2. Phenotypic analysis ofTLA' IEL. IEL were prepared as
described from B10.BR mice, and 106 cells were stained. The
lymphocyte population was gated, and 5000 events were analyzed on
a FACScan flow cytometer. (Upper Left) Profile seen with strepta-
vidin-phycoerythrin alone. Incubation first with biotinylated TL.m9
and then with streptavidin-phycoerythrin and FITC-conjugated
mAb Thy-1.2 (anti-Thy-1) (Upper Right), FITC-conjugated mAb
H57-597 (anti-af3 TCR) (Lower Left), or FITC-conjugated mAb GL3
(anti-y6 TCR) (Lower Right). Scale logarithms (to base 10) indicate
percent of cells in each quadrant.
surface expression of TLA. Moreover, staining density ap-
peared more concentrated along the basal aspect of the
epithelial layer. Both crypt cells and tip cells stained brightly,
whereas the glandular epithelium, the lamina propria, and
Peyer's patches did not stain. This contrasted markedly with
the staining from the anti-a13 TCR antibody; this antibody
stained only T lymphocytes in the lamina propria, epithelia,
and T-cell regions of Peyer's patches but did not stain the
epithelial cells (Fig. 3A). The haplotype specificity of these
antibodies in tissue sections also followed that described for
thymocytes (Table 1) and IEL preparations. A similar pattern
of cell-surface staining of the luminal epithelium was seen
throughout the small intestine. TLA expression was not seen
when sections of other epithelia reported to contain T cells
expressing y6 TCR (11), including tongue, esophagus, stom-
ach, and female reproductive tract, were examined by this
technique (data not shown).
To examine the role, if any, of lymphocytes in modulating
expression of TLA by the epithelial cells, we stained intes-
tinal tissue derived from scid/scid mice. The scid/scid mice
did not contain any lymphocytes expressing af TCR in the
lamina propria or within the intestinal epithelium (data not
shown). However, the staining pattern with the TLA mAb in
scid/scid mice was identical to that seen in normal mice (Fig.
3C). This result indicates that TLA expression in intestinal
epithelial cells is independent of the presence of mature
functional T lymphocytes within the epithelium or lamina
propria.
PCR Analysis of TLA Gene Expression. To confirm these
results at the transcriptional level we performed PCR on
cDNA from a variety of mouse tissues. Using primers
specific for individual Tla genes, we were also able to
investigate whether other Tla genes that encode products not
recognized by available antibodies are transcribed in our IEL
preparations. Because Tla genes appear inefficiently spliced
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FIG. 3. Immunohistochemical analysis of small intestine sec-
tions. Sections (5 Am) were prepared from the intestine of BALB/c
and BALB/c scid/scid mice as described. The H202-induced, per-
oxidase-dependent conversion ofthe colorimetric substrate results in
the red color indicating the serological determinant recognized by the
antibody. Mayer's hematoxylin counterstain results in the purple
appearance of the cell nuclei. (A) Biotinylated mAb H57-597 staining
of BALB/c mouse section. (B) Biotinylated mAb TL.m4 staining of
BALB/c mouse section. (C) Biotinylated mAb TL.m4 staining of
BALB/c scid/scid mouse section. (x 100.)
in some tissues (27), it was of interest that both spliced and
unspliced RNA were detected by using this technique. An
example of this type of analysis with primers derived from
exons 2 and 3 of T18d, which are specific for this gene, is
shown in Fig. 4. Both spliced and unspliced T18d mRNA is
seen in thymus (lane 1). Moreover, both unspliced and
spliced T18d mRNA was also seen in IEL preparations (lane
6). As the IEL preparations contain both lymphocytes and
epithelial cells, this technique does not determine which cell
type gives rise to the T18d transcript. Nevertheless, this
result is consistent with the staining pattern we observed in
preparations ofthymocytes and IEL with the TLA mAbs that
appear to recognize the product of T18d. No spliced T18d gene
transcripts were seen in adult liver, brain, heart, or mesen-
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FIG. 4. PCR analysis of T18d gene expression in IEL prepara-
tions. Ten-microliter aliquots of PCR reactions with primers specific
for T18d were electrophoresed on 2% agarose gel and transferred to
a nylon membrane, as described. The membrane was then hybridized
with T3V/T18"-specific DNA probe pTla 4, washed stringently, and
exposed for autoradiography. Lanes: 1, thymus; 2, liver; 3, heart; 4,
brain; 5, mesenteric lymph node; and 6, IEL preparation. Exposure
time was 18 hr. nt, Nucleotides.
teric lymph nodes or several other tissues tested (data not
shown).
We have performed similar analyses with primers specific
for several other genes in the Tia gene region. We detected
spliced mRNA in IEL preparations for both the TlJO/22d
gene pair (the members of which cannot be distinguished by
PCR) and the M2 gene (encoded in the Himt region of the
MHC) (28). In contrast, no unspliced or spliced mRNA in
IEL is seen by using primers specific for the Tid, T2d, T16d,
T17d, or 724d genes (data not shown).
DISCUSSION
In this study we show that both intestinal epithelial cells and
a significant fraction of IEL express the TLA on their
surface. These observations were based on staining with
three different anti-TLA mAbs in both single-cell suspen-
sions and by in situ histochemical analysis. Reactivity of
these antibodies in IEL preparations and intestinal sections
followed the strain-distribution pattern we and others have
seen in thymocytes. This result argues strongly that this
staining pattern cannot be simply a cross-reactivity with
another cell-surface antigen, unless it were closely linked
genetically and, therefore, followed the identical strain dis-
tribution as TLA. Moreover, we confirmed by PCR analysis
that spliced T18d transcripts are present in the intestine and
in the thymus, although absent from many other tissues
tested.
The expression ofTLA in a population of mature lympho-
cytes in the intestinal epithelium is somewhat surprising in
the context of the lack ofTLA expression in other peripheral
sites (e.g., lymph nodes and Peyer's patches). TLA expres-
sion has been reported to be induced in splenic T cells in vitro
after treatment with Con A (4). These data suggest that TLA
may be a marker of, or play some role in, T-cell activation.
In our study, most of the IEL expressing afB TCR and a lesser
proportion of the IEL expressing y8 TCR express TLA.
Lefrancois and Goodman (29) have reported that a population
of IEL are constitutively lytic. This lytic activity was hy-
pothesized to result from in vivo activation and was subse-
quently shown to be independent of the type of TCR ex-
pressed (i.e., car or y6) (30). The activated IEL in these
studies were believed to be Thy-1+ (26). IfTLA were, indeed,
a marker of IEL activation, the presence of TLA on a
significant fraction of IEL would be consistent with these
observations. However, most of the TLA' IEL in our
preparations are Thy-1-. An alternative explanation for the
TLA expression profile in IEL is that the TLA' and TLA-
lymphocytes are derived from distinct lineages of T lympho-
cytes (i.e., thymic or extrathymic).
Proc. Natl. Acad. Sci. USA 87 (/990)
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The presence of the TLA on the surface of epithelial cells
in the mouse small intestine extends the known profile of
expression of this molecule. Previously, TLA has been
detected only in cells of the hematopoietic lineage, including
T cells and Langerhans cells of the skin (31). Transcripts of
some other Tia region genes that do not encode serologically
detectable proteins have been shown to have a wider tissue
distribution at the RNA level (32-34). However, in these
instances, the cell type expressing the Tla-encoded gene
product on its surface has not been identified.
The presence of TLA on the surface of the intestinal
epithelium is especially interesting in view of recent reports
by several groups describing y6 T-cell lines or T-cell hybrid-
omas alloreactive to or restricted to products ofthe Tla region
of the MHC (6-8). IEL are predominantly CD4-CD8' and,
therefore, are likely to interact with class I or class I-like
molecules. It is tempting to speculate, as others have (9, 10),
that the products of Tla genes may be involved in presenting
peptide antigens to T cells bearing 'y6 TCR. Tia gene products
could also have a role in antigen presentation to T cells
bearing a/3 TCR. It has been recently reported that Tla
molecules can be involved in the negative selection ofy3TCR
expression in transgenic mice (35). As yH IEL are seen in
nu/nu mice and may, therefore, mature extrathymically (36),
TLA could also be involved in the education of 'yO T cells in
the intestinal epithelium.
Mayer and Schlein (37) have shown that intestinal epithe-
lial cells can function as antigen-presenting cells to splenic or
peripheral blood-derived T cells in vitro. It is, therefore,
likely that intestinal epithelial cells are involved in the
presentation of antigen to lymphocytes present within the
epithelial barrier in vivo. Although the present data do not
provide direct support for the hypothesis that Tla gene
products can present antigen to T cells that express y8 TCR,
the demonstration of TLA on putative antigen-presenting
cells in an anatomical site enriched for such cells makes the
hypothesis tenable. These data extend the possible functional
role for TLA beyond the proposed role in T-cell development
and/or proliferation.
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